Novel benzoxazines as inhibitors of angiogenesis

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 45-52

  Al Rawi, Sara ^a   Meehan Andrews, Terri ^a   Bradley, Chris ^a   Al Rawi, Jasim ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

Angiogenesis; HUVECs; Migration; PI3K; Proliferation; Tube formation

Indexed keywords

BENZOXAZINE DERIVATIVE; ENDOSTATIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GELATINASE B; INTERLEUKIN 8; LTUSI 118; LTUSI 122; LTUSI 58; LTUSI 99; LTUT 1; LTUT 3; LTUT 4; LTUT 5; MONOCYTE CHEMOTACTIC PROTEIN 4; PHOSPHATIDYLINOSITOL 3 KINASE; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; CCL13 PROTEIN, HUMAN; CXCL5 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; MONOCYTE CHEMOTACTIC PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; CELL CULTURE; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; BENZOXAZINES; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; CHEMOKINE CXCL5; ENDOSTATINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 9; MONOCYTE CHEMOATTRACTANT PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84922099130     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0172-8     Document Type: Article

References (23)

1. Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE, Hall DM (2010) Molecular interactions in cancer cell metastasis. Acta Histochem 112(1):3-25
2. Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33(4):207-14
3. Krock BL, Skuli N, Simon MC (2011) Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2(12):1117-33
4. Chen HH, Zhou HJ, Fang X (2003) Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res: Off J Ital Pharmacol Soc 48(3):231-6
5. Sieczkiewicz GJ, Hussain M, Kohn EC (2002) Angiogenesis and metastasis. Cancer Treat Res 107:353-81
6. Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28(11):1779-802
7. Roskoski R Jr (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356(2):323-8
8. Hyunseung L, Kyung J, Yujeong J, Sungwoo H, Soon-Sun H (2013) HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. Cancer Lett 328(1):152-9
9. Graupera M, Guillermet-Guibert J, Foukas LC, Phng L-K, Cain RJ, Salpekar A et al (2008) Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature 453(7195):662-6
10. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606-619
11. Cook KM, Figg WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60(4):222-43
12. Karar J, Maity A (2011) PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4:51
13. Fitzgibbon C, Ihmaid S, Al-Rawi J, Meehan-Andrews T, Bradley C (2013) Chemo-sensitisation of HeLa cells to etoposide by a benzoxazine in the absence of DNA-PK inhibition. Investig New Drugs 31(6):1466-75
14. Abcam. Human Angiogenesis Antibody Array-Membrane (23 Target) 2014 Available from: http://www.abcam.com/human-angiogenesis-antibody-array-membrane-23-targets-ab169808.html
15. Abcam. Human Angiogenesis Antibody Array - Membrane (20 Targets) 2014 Available from: http://www.abcam.com/human-angiogenesis-antibody-array-membrane-20-targets-ab134000.html
16. Folkman J (2007) Angiogenesis: an organising principle for drug discovery? Nat Rev Drug Discov 6:273-286
17. Samant RS, Shevde LA (2011) Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2(3):122-134
18. Xue Y, Li N-L, Yang J-Y, Chen Y, Yang L-L, Liu W-C (2011) Phosphatidylinositol 3'-kinase signaling pathway is essential for Rac1-induced hypoxia-inducible factor-1α and vascular endothelial growth factor expression. Am J Physiol Heart Circ Physiol 300(6):H2169-H76
19. Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT et al (2005) Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer 93(9):1011-8
20. Ihmaid SK, Al-Rawi JMA, Bradley CJ, Angove MJ, Robertson MN (2012) Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines. Eur J Med Chem 57:85-101
21. Dong Z, Cheng Y, Zhao J, Su L, Zhao B, Zhang Y et al (2010) Discovery of a benzoxazine derivative promoting angiogenesis in vitro and in vivo. J Cell Physiol 223(1):202-8
22. Mannell H, Hammitzsch A, Mettler R, Pohl U, Krotz F (2010) Suppression of DNA-PKcs enhances FGF-2 dependent human endothelial cell proliferation via negative regulation of Akt. Cell Signal 22(1):88-96
23. Morrison R, Belz T, Ihmaid S, Al-Rawi JA, Angove M (2014) Dual and/or selective DNA-PK, PI3K inhibition and isoform selectivity of some new and known 2-amino-substituted-1,3-benzoxazines and substituted-1,3-naphthoxazines. Med Chem Res 24:1-12